Stories tagged “Biotechnology.”
26 stories
This edition of The Download highlights breakthroughs in biotechnology, including innovations in vision restoration and gene editing, alongside a new method for producing cheaper, cleaner steel.
MIT Technology Review unveils its 2026 '35 Innovators Under 35' list, recognizing global talent in biotechnology, AI, computing, robotics, and climate and energy. The edition also features key tech news, including AI funding, chip developments, and energy consumption conc…
Rising fossil fuel prices, exacerbated by geopolitical conflict in Iran, are driving up fertilizer costs, which in turn increases food prices globally. Microbe-based alternatives are emerging but face limitations.
Moderna's stock surged 131% after the Phase 3 INTerpath-001 trial of intismeran autogene plus Keytruda hit its RFS and DMFS endpoints in resected melanoma.
Amylyx Pharmaceuticals' experimental drug avexitide sharply reduced dangerously low blood sugar episodes in a late-stage trial of patients who underwent weight-loss surgery.
Scientists have identified imidazole propionate (ImP), a molecule produced by certain gut bacteria, as a potential link between the gut microbiome and Alzheimer's disease.
Prime Medicine trades at a $548M valuation despite a 54% stock decline from 52-week highs. They have continued to clear IND/CTA and receive RMAT designation for their gene-editing pipeline targeting liver, lung, and immunology/oncology indications.
10x Genomics (TXG) reported Q2 2026 earnings, raising full-year revenue guidance despite expected sequential decline in the third quarter. Booked orders for the new Atera platform have surpassed the 2026 shipment target, though manufacturing capacity limits remain a const…
Researchers from the National University of Singapore (NUS) have developed a red light-responsive protein called y-iLight that controls gene activity in yeast without extra chemicals. This breakthrough makes biomanufacturing more reliable and eco-friendly.
Researchers at Stanford University have successfully designed new, replicable viruses using artificial intelligence. This breakthrough marks the first time AI has designed a complete virus genome. The team created 16 new viruses that target bacteria, with no threat to hum…
The 27th Iran Health International Exhibition will be held from August 8 to 11 at the Tehran Permanent International Fairground, showcasing the latest technological achievements in the healthcare sector.
A Montana law allows people to access unapproved drugs, which could help a father, Kris DeVault, get his son, Brody, a treatment for a rare condition. However, the law has its limitations, and DeVault is considering other options.
Buckley Capital Advisors highlighted Liquidia Corporation (NASDAQ: LQDA) in its second-quarter 2026 investor letter, citing 50%+ upside on Yutrepia ruling and buyout potential.
A team of researchers has successfully preserved pig kidneys at -4°C for days, a major breakthrough in the quest to keep organs alive outside the body. This achievement could lead to the development of organ banks, where human organs can be preserved for days, weeks, or e…
Wall Street funds, including BlackRock and JPMorgan Chase, have increased their stakes in Chinese pharmaceutical contractor WuXi AppTec, betting on a surge in weight-loss drug manufacturing orders.
CRISPR Therapeutics offers a diversified gene-editing pipeline with CASGEVY as its lead approved asset and multiple upcoming catalysts. The company's valuation reflects a 38% drawdown from its 52-week high, while several clinical data readouts and trial initiations are im…
Vertex Pharmaceuticals has acquired Crinetics Pharmaceuticals for $10 billion, gaining access to products for endocrine diseases and a pipeline of promising candidates. This move diversifies Vertex's portfolio and could drive strong financial results.
Iovance Biotherapeutics is showing steady operational and financial progress, supporting a speculative Buy rating upgrade. Q1 revenue reached $71.4M, with Amtagvi generating $60M; the sequential dip was attributed to one-off events, not demand weakness.
Pharmaceuticals/biotechnology valuations and quality are near 11-year historical baselines, while healthcare equipment appears undervalued and life science tools least attractive. State Street SPDR S&P Pharmaceuticals ETF offers diversified pharmaceutical exposure with a …
Two beaten-down stocks, Recursion Pharmaceuticals and Sarepta Therapeutics, are not worth buying despite their potential for long-term gains. Both companies face significant challenges, including clinical and regulatory setbacks, and are not attractive investments for mos…
The paper introduces Design-CP, a method using context-parallel inference strategies for RFdiffusion 3 to overcome GPU memory limitations in designing large multimeric protein complexes. It enables the all-atom design of complex protein nanoparticles like icosahedral and …
Iran and China, through their respective science foundations, will jointly fund 15 research projects in critical areas like water, energy, and biotechnology, with each project receiving approximately $28,800 over three years. This initiative follows their sixth joint call…
Iran has launched a cell therapy product made from umbilical cord-derived stem cells for treating osteoarthritis. The product, WhartoCell, was developed by researchers at Royan Institute.
Allarity Therapeutics, Inc. held its 2026 Annual Meeting of Stockholders, where CEO Thomas Jensen discussed the company's progress and future plans. The meeting included a presentation by CFO Jeffrey Ervin.
Zenas BioPharma's CEO, Leon Molder, purchased 60,000 company shares at a weighted average price of $16.88 per share. This transaction suggests a bullish outlook towards the stock.
Boston startups raised about $7.8 billion so far this year, but the gain looks modest beside the AI-fueled boom concentrated in San Francisco.